Ignite Creation Date:
2025-12-24 @ 3:00 PM
Ignite Modification Date:
2025-12-30 @ 8:18 AM
Study NCT ID:
NCT01174459
Status:
COMPLETED
Last Update Posted:
2014-08-29
First Post:
2010-08-02
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Survey on Long-Term Use of BI-Sifrol® Tablets in Patients With Restless Legs Syndrome
Sponsor:
Boehringer Ingelheim
Organization:
Study Overview
Official Title:
Survey on Long-Term Use of BI-Sifrol® Tablets in Patients With Restless Legs Syndrome
Status:
COMPLETED
Status Verified Date:
2014-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The survey is conducted to investigate the safety and efficacy of long-term use of BI-Sifrol Tablets in Restless Legs Syndrome (RLS) patients with or without renal dysfunction in routine medical practice.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: